<DOC>
	<DOCNO>NCT00316927</DOCNO>
	<brief_summary>RATIONALE : Giving dexamethasone together aspirin diethylstilbestrol may effective lower prostate-specific antigen level may slow stop growth prostate cancer . It yet know schedule dexamethasone , aspirin , diethylstilbestrol effective treat prostate cancer . PURPOSE : This randomized phase III trial study dexamethasone aspirin give together two different schedule diethylstilbestrol compare well work treat patient locally advance metastatic prostate cancer .</brief_summary>
	<brief_title>Dexamethasone , Aspirin , Diethylstilbestrol Treating Patients With Locally Advanced Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare prostate-specific antigen ( PSA ) response patient locally advance metastatic prostate cancer treat dexamethasone aspirin delay v immediate diethylstilbestrol . Secondary - Compare overall response rate patient treat regimen . - Compare quality life patient treat regimen . - Compare progression-free overall survival patient treat regimen . OUTLINE : This randomize , control , multicenter study . Patients stratify accord ECOG performance status ( 0 vs 1-3 ) , prostate-specific antigen ( PSA ) response prior therapy ( PSA normalization v inability normalize ) , bone scan ( positive v negative bony metastasis ) . Patients randomize 1 2 treatment arm . - Arm I ( defer diethylstilbestrol ) : Patients receive oral dexamethasone oral acetylsalicyclic acid daily ( DA ) . Subsequent treatment failure DA , patient continue receive DA addition oral diethylstilbestrol daily ( DAS ) . Treatment DAS continue absence disease progression unacceptable toxicity . - Arm II ( immediate diethylstilbestrol ) : Patients receive oral dexamethasone , oral acetylsalicyclic acid , oral diethylstilbestrol daily ( DAS ) . Treatment continue absence disease progression unacceptable toxicity . Quality life evaluate monthly study treatment . After completion study treatment , patient follow every 3 month 1 year every 6 month thereafter . PROJECTED ACCRUAL : A total 260 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Fosfestrol</mesh_term>
	<mesh_term>Diethylstilbestrol</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis adenocarcinoma prostate Elevated prostatespecific antigen ( PSA ) Failed previous treatment , include gonadatropan regulatory hormone analogue therapy , radiotherapy , surgery , combination Biochemically castrate ( testosterone &lt; 1 nmol/L ) baseline PATIENT CHARACTERISTICS : Life expectancy ≥ 3 month ECOG performance status 03 WBC ≥ 3,000/mm^3 Absolute neutrophil count ( neutrophils band ) ≥ 2,000/mm^3 Platelet count ≥ 50,000/mm^3 Bilirubin ≤ 2 time upper limit normal ( ULN ) AST ALT ≤ 3 time ULN Creatinine ≤ 1.5 time ULN Able swallow tablet No malignancy within past 3 year except basal cell skin cancer No previous thromboembolic disease , include stroke , venous arterial thrombosis , myocardial infarction ongoing angina pectoris Prior uncomplicated myocardial infarction allow No diabetes mellitus treatment titration think difficult inappropriate No active gastric duodenal ulcer PRIOR CONCURRENT THERAPY : See Disease Characteristics Prior concurrent bisphosphonates allow No concurrent investigational agent participation another investigational drug study No concurrent antineoplastic therapy , include new estrogen therapy , radiation therapy , PCSPES No concurrent corticosteroid ( e.g. , dexamethasone nausea vomit ) except prescribe study regimen</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>